| Vol. 14.36 – 23 September, 2020 |
| |
|
|
| Researchers report a neurotechnology for selective epineural optogenetic neuromodulation of nociceptors and demonstrated that nociceptor activation drove both protective pain behavior and inflammation. [Nature Biotechnology] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors developed light-sensitive human retinal organoids with multiple nuclear and synaptic layers and functional synapses. [Cell] |
|
|
|
| Scientists investigated the susceptibility of human iPSC-derived monolayer brain cells and region-specific brain organoids to SARS-CoV-2 infection. [Cell Stem Cell] |
|
|
|
| Investigators revealed insights into the activity of microRNAs miR-9/9 and miR-124 as reprogramming agents that orchestrated direct conversion of human fibroblasts into motor neurons by first eradicating fibroblast identity and promoting uniform transition to a neuronal state in sequence. [Cell Stem Cell] |
|
|
|
| Scientists transplanted hESC-derived midbrain dopamine or cortical glutamate neurons into the substantia nigra or striatum of a mouse Parkinson’s disease model and found extensive graft integration with host circuitry [Cell Stem Cell] |
|
|
|
| The authors showed that glia could be reprogrammed to promote morphological and functional regeneration after central nervous system injury in Drosophila via increased glycolysis. [Cell Metabolism] |
|
|
|
| Scientists identified specific hypothalamic neurons required for sensing conspecific male cues relevant to inter-male aggression. [Neuron] |
|
|
|
| Researchers presented the results of a high-content siRNA microscopy screen, revealing the transcriptional elongation factor SPT6 to be critical for the genomic stability and self-renewal of glioblastoma cancer-stem like cells. [Nature Communications] |
|
|
|
|
| Scientists suggested that artificial cells were a versatile chassis for the in situ synthesis and on-demand release of chemical signals that elicited desired phenotypic changes of eukaryotic cells, including neuronal differentiation. [Science Advances] |
|
|
|
| Researchers demonstrated that the autophagy-lysosome axis was the primary mode for the clearance of aggregated species of MAPT using both chemical and genetic approaches in cell models of amyloid MAPT aggregation. [Autophagy] |
|
|
|
| High‐performance secretome protein enrichment with click sugars method was used to identify the secretory response of brain slices upon LPS‐induced neuroinflammation and to establish the cell type‐resolved mouse brain secretome resource using primary astrocytes, microglia, neurons, and oligodendrocytes. [EMBO Journal] |
|
|
|
|
| The authors discuss the current studies using human pluripotent stem cells focused on Alzheimer’s disease (AD), providing convincing evidences that this system is an excellent opportunity to advance in the comprehension of AD pathology, which will be translated to the development of the still missing effective therapies. [International Journal of Molecular Sciences] |
|
|
|
|
|
Seelos Therapeutics, Inc. announced the signing of a Sponsored Research Agreement with Duke University to use the MPTP-induced Parkinson’s Disease (PD) mouse model to establish in vivo proof-of-concept study to demonstrate that administration of LV-dCas9-DNMT3A virus can prevent and/or delay PD and test the efficacy and safety of SLS-004. [Seelos Therapeutics Inc.] |
|
| Zhittya Genesis Medicine, Inc announced that it will initiate clinical trials to test a medical hypothesis that has been advanced over the last five years that Parkinson’s disease may be caused by vascular disruption in the areas of the brain which house the “dopamine-producing neurons”, those neurons which become dysfunctional in patients suffering from this disorder. [Zhittya Genesis Medicine, Inc. (GlobeNewswire, Inc)] |
|
|
| |
| ProMIS Neurosciences, Inc. announced initiation of a program to construct and test a multivalent peptide vaccine for Alzheimer’s disease. The critical first steps in vaccine development was carried out by VIDO-InterVac, a global leader in vaccine research and development. [ProMIS Neurosciences, Inc.] |
|
|
|
|
| December 2 – December 4 Virtual |
|
|
|
|
|
| University Hospital Basel – Basel, Switzerland |
|
|
|
| The Francis Crick Institute – London, United Kingdom |
|
|
|
| The Francis Crick Institute – London, United Kingdom |
|
|
|
| Icahn School of Medicine at Mount Sinai – New York, New York, United States |
|
|
|
| Nanyang Technological University – Singapore, Singapore |
|
|
|
|